Aerobidol Drug Interactions

Other beta-agonist, anticholinergics and xanthine derivatives: Concurrent use may enhance the pharmacological effect and adverse reactions.
Beta- adrenergic blocking agents: A potentially serious reduction in bronchodilation may occur during concurrent administration of beta- adrenergic blocking agents as: Ophthalmic beta-adrenergic blocking agents, which are absorbed systemically via the nasolacrimal duct. Respiratory complications associated with the use of timolol have been reported and include bronchospasm, dyspnea, wheezing, decreased pulmonary function, and respiratory failure; therefore, concurrent use may result in inhibition of the betaadrenergic effects of the adrenergic bronchodilators and worsening of bronchospasm).
Systemic beta-adrenergic blocking agents: concurrent use with adrenergic bronchodilators may result in mutual inhibition of therapeutic effects; beta-blockade may antagonize the bronchodilating effect of these bronchodilators; although antagonists with beta1-selectivity may be less antagonistic, extreme caution is recommended if these agents are used in patients with bronchospasm because beta-adrenergic blocking agents may induce bronchospasm.
Corticosteroids, Non potassium-sparing diuretics or Methylxanthines and other xanthine derivatives: Beta-agonist-induced hypokalemia may be increased by concomitant treatment with xanthine derivatives, corticosteroids and diuretics especially in patients with severe asthma. This should be taken into account particularly in patients with severe airway obstruction.
Digoxin: The patients on digitalis glycoside such as digoxin may be more susceptible to arrhythmias due to hypokalemic result when use the drug. Serum potassium level should be monitored periodically.
Monoamine oxidase inhibitors or tricyclic antidepressants: Beta2-agonists containing medicinal products should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or when beta-adrenergic agonists is given within 2 weeks of discontinuing these agents, since the action of beta-adrenergic agonists on the vascular system may be potentiated by these agents.
Halogenated hydrocarbon anesthetics: Beta-agonists should be used with caution in patient during inhalation of halogenated hydrocarbon anesthetics such as halothane, trichloroethylene and enflurane since may increase cardiovascular adverse effects.
Laboratory value alterations: Electrocardiogram: transient ventricular premature contractions, atrial arrhythmia, inverted T waves, junctional rhythm, and prolongation of the QTc interval are reported rarely with adrenergic bronchodilators; effects may be more pronounced following frequent use of higher doses or an overdose; arrhythmias may also result from hypoxia or hypokalemia.
Blood Glucose: Blood glucose concentrations may be increased, possibly due to glycogenolysis; clinically significant changes may be more pronounced following with frequent use of higher doses or an overdose.
Serum Potassium: serum potassium concentrations may be decreased, possibly through intracellular shunting; the decrease is dose-related, is usually transient, and may not require supplementation; effects may be more pronounced following with frequent use of higher doses or an overdose.